Tempo Therapeutics, headquartered in San Diego, California, is pioneering a new era in tissue engineering biotechnology with its proprietary MAP (Microporous Annealed Particle) material science technology. The company's core mission is to use MAP technology to enable the creation of functional tissues and organs within patients in real-time to treat various diseases. Additionally, Tempo is developing next-generation vaccine technologies that are shelf-stable, stockpile-able, and capable of protecting against multiple diseases with a single injection. Their market focus includes regenerative medicine and advanced vaccine solutions.
Notable affiliated people and investors include leading experts in biotechnology and regenerative medicine, though specific names are not provided. Key achievements of Tempo Therapeutics include the development of their first-in-class volumetric injectable porous scaffolding, which represents a significant advancement in the field of regenerative medicine. The overall impact of Tempo's innovations lies in their potential to revolutionize how diseases are treated and how vaccines are developed and distributed, offering more effective and accessible healthcare solutions.
Quick Facts
When was Tempo Therapeutics' last funding round?
Tempo Therapeutics' most recent funding round was for $256k (USD) in September 2020.
How much disclosed funding has Tempo Therapeutics raised?
As of Sep 2, 2020, Tempo Therapeutics has disclosed funding of $4.1M (USD).
